Medicenna Therapeutics (MDNAF) Stock Price, News & Analysis

Company Overview

Medicenna Therapeutics Corp. is a Canadian clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s research is based on its Superkine platform, which is designed to modify cytokines—immune-signaling proteins—to improve their ability to stimulate anti-tumor immune responses while addressing limitations associated with conventional cytokine therapies.

Medicenna’s lead product candidate is MDNA11, a long-acting, beta-biased interleukin-2 (IL-2) agonist being developed for the treatment of advanced solid tumors. The therapy is intended to selectively activate immune cells involved in cancer control, including natural killer cells and tumor-reactive T cells. Medicenna has also developed MDNA55, an investigational targeted toxin designed to deliver an anti-cancer payload to cells expressing the interleukin-4 receptor, with a focus on difficult-to-treat brain tumors.

Founded in Canada, Medicenna conducts its research and clinical development activities through collaborations and clinical programs in North America and other relevant markets. Fahar Merchant, Ph.D., is the company’s co-founder and chief executive officer. Medicenna Therapeutics is headquartered in Vancouver, British Columbia, and its shares trade in Canada and on the U.S. over-the-counter market under the symbol MDNAF.

Key Stats

• Today's Range: $0.30 to $0.32
• 50-Day Range: $0.25 to $0.35
• 52-Week Range: $0.23 to $1.43
• Volume: 22,979 shs
• Average Volume: 56,962 shs
• Market Capitalization: $29.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Medicenna Therapeutics Stock Analysis - MarketRank™

Medicenna Therapeutics scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Medicenna Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Medicenna Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Medicenna Therapeutics are expected to grow in the coming year, from ($0.17) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Medicenna Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medicenna Therapeutics is -1.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medicenna Therapeutics has a P/B Ratio of 15.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.80% of the float of Medicenna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Medicenna Therapeutics has a short interest ratio ("days to cover") of 6.37.

Change versus previous month

Short interest in Medicenna Therapeutics has recently decreased by 1.55%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medicenna Therapeutics does not currently pay a dividend.

Dividend Growth

Medicenna Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.8 / 5
• News Sentiment: N/A

News Sentiment

Medicenna Therapeutics has a news sentiment score of -0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Medicenna Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.10% of the stock of Medicenna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

35.85% of the stock of Medicenna Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 6/25/2026
• Today: 10/09/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MDNAF
• CIK: 1807983
• Web: www.medicenna.com
• Phone: (416) 648-5555
• Fax: 416-572-7501
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.16)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.32 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1.38%
• Return on Assets: -0.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.25
• Quick Ratio: 1.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: 15.80

Miscellaneous

• Outstanding Shares: 92,300,000
• Free Float: 61,749,000
• Market Cap: $29.17 million
• Optionable: N/A
• Beta: 1.97